Literature DB >> 1629416

CT of melanoma liver metastases: is the examination without contrast media superfluous?

J J Chomyn1, E R Stamm, D Thickman.   

Abstract

The current method of evaluating hypervascular liver metastases with CT includes both contrast enhanced and unenhanced studies. The necessity of performing both examinations for the detection of liver metastases in the workup of malignant melanoma has not been specifically addressed. This study evaluates potential additional information derived from an unenhanced examination of the liver. We studied 55 patients with malignant melanoma who had both contrast enhanced and unenhanced CT examinations performed during the workup and staging of their disease. Sixteen patients had 89 measurable liver lesions seen on enhanced CT. Three patients had liver lesions that were too numerous to accurately measure. Unenhanced CT demonstrated only 62% of the measurable lesions. All liver lesions seen on the unenhanced images were identified on the enhanced studies. Only one metastasis was found to be comparatively smaller on the enhanced examinations. The unenhanced examinations detected no additional lesions. It is reasonable to perform only an enhanced examination during the workup and staging of malignant melanoma liver metastases.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1629416     DOI: 10.1097/00004728-199207000-00013

Source DB:  PubMed          Journal:  J Comput Assist Tomogr        ISSN: 0363-8715            Impact factor:   1.826


  2 in total

1.  Assessment of Added Value of Noncontrast to Contrast-Enhanced Abdominal Computed Tomography Scan for Characterization of Hypervascular Liver Metastases.

Authors:  Gelareh Sadigh; Sadhna B Nandwana; Courtney Moreno; Kelly L Cox; Deborah A Baumgarten; Jeffrey Switchenko; Tiffany Easter; Kimberly E Applegate
Journal:  Curr Probl Diagn Radiol       Date:  2016-05-25

2.  Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma.

Authors:  Jacqueline Dinnes; Lavinia Ferrante di Ruffano; Yemisi Takwoingi; Seau Tak Cheung; Paul Nathan; Rubeta N Matin; Naomi Chuchu; Sue Ann Chan; Alana Durack; Susan E Bayliss; Abha Gulati; Lopa Patel; Clare Davenport; Kathie Godfrey; Manil Subesinghe; Zoe Traill; Jonathan J Deeks; Hywel C Williams
Journal:  Cochrane Database Syst Rev       Date:  2019-07-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.